Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Biden Administration, New Congress Review Recent Rules Affecting Cancer Care Delivery

Oncology Practice Insider

In the days and weeks leading up to President Biden’s inauguration, the Department of Health and Human Services (HHS)—under the prior administration—issued a number of rules and regulations that affect cancer care delivery. Many of those rules and regulations are now subject to review by the new administration and/or Congress.

The Biden administration issued a regulatory freeze on all rules, guidance, and other agency actions that had not taken effect prior to January 20, 2021 at 12:00 PM (ET). If a rule is pending or not yet published in the Federal Register, the new administration may withdraw the rule or review it before sending it to the Federal Register and for implementation.

Implementation of rules that have been published in the Federal Register but have not yet taken effect may be delayed for 60 days. During the delay, the administration may open a 30-day comment period to gather stakeholder feedback on the rules. Alternatively, if no further action is needed, the rule, proposal, or guidance will be considered active and effective.

In addition to the Biden Administration’s regulatory freeze, the Congressional Review Act permits the incoming Congress to review final rules issued within the first 60 days of the new Congress as well as rules issued during the last 60 days of the previous Congress. Read more.